Skip to main content

Fresenius is further expanding its access to innovation networks through its own corporate venture capital fund. Fresenius Ventures invests in founders, technologies, and business models from early financing rounds through to the growth stage. The newly established unit combines venture capital with medical, regulatory, and operational expertise and provides access to clinical, scientific, and academic networks.

With an intended investment volume of more than €200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision. Potential investment areas of Fresenius Ventures include, for example, precision nutrition, microbiome research, new modalities, and digital care provision solutions. Investments will be made in line with Fresenius’ capital allocation approach.

Michael Sen, CEO of Fresenius, says: “Fresenius Ventures is a strategic instrument of #FutureFresenius. Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent. This step enables us to strengthen our innovation capabilities within the healthcare ecosystem and tap into adjacent growth fields while consistently strengthening Fresenius. I am delighted that Dr. Thomas Michael Thestrup, a highly experienced healthcare and corporate venture capital expert, will lead Fresenius Ventures.” 

Thomas Michael Thestrup joins Fresenius from Angelini Ventures, an international healthcare venture capital company and part of the Italian industrial group Angelini Industries.

“Fresenius Ventures backs the innovators shaping the next era of healthcare with the experience, pace, and conviction founders expect. We offer more than capital: deep operating and regulatory expertise across global markets, coupled with access to the clinical, scientific, and academic ecosystems where real progress happens today,” says Thomas Thestrup, Managing Director and Head of Fresenius Ventures.

Thomas Thestrup has more than 15 years of experience in research, health tech, and the pharma industry. Prior to Angelini Ventures, he worked for Lundbeck A/S as Director of Corporate Business Development and Strategy. Further positions prior to this include Global Business Development at UCB as well as Life Science Ventures at Sunstone Capital. Thomas Thestrup received his Ph.D. from the Max Planck Institute of Neurobiology in Munich.

For more information about Fresenius Ventures, please see: fresenius- ventures.com

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

 

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

 

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu

Chairman of the Supervisory Board: Wolfgang Kirsch

Fresenius is further expanding its access to innovation networks through its own corporate venture capital fund. Fresenius Ventures invests in founders, technologies, and business models from early financing rounds through to the growth stage. The newly established unit combines venture capital with medical, regulatory, and operational expertise and provides access to clinical, scientific, and academic networks.

With an intended investment volume of more than €200 million over the next 5 years, Fresenius Ventures targets growth fields adjacent to Fresenius’ existing strategic platforms (Bio)Pharma, MedTech, and Care Provision. Potential investment areas of Fresenius Ventures include, for example, precision nutrition, microbiome research, new modalities, and digital care provision solutions. Investments will be made in line with Fresenius’ capital allocation approach.

Michael Sen, CEO of Fresenius, says: “Fresenius Ventures is a strategic instrument of #FutureFresenius. Through targeted investments in promising healthcare innovators, we gain early access to breakthrough technologies, new ideas, and entrepreneurial talent. This step enables us to strengthen our innovation capabilities within the healthcare ecosystem and tap into adjacent growth fields while consistently strengthening Fresenius. I am delighted that Dr. Thomas Michael Thestrup, a highly experienced healthcare and corporate venture capital expert, will lead Fresenius Ventures.”

Thomas Michael Thestrup joins Fresenius from Angelini Ventures, an international healthcare venture capital company and part of the Italian industrial group Angelini Industries. 

“Fresenius Ventures backs the innovators shaping the next era of healthcare with the experience, pace, and conviction founders expect. We offer more than capital: deep operating and regulatory expertise across global markets, coupled with access to the clinical, scientific, and academic ecosystems where real progress happens today,” says Thomas Thestrup, Managing Director and Head of Fresenius Ventures. 

Thomas Thestrup has more than 15 years of experience in research, health tech, and the pharma industry. Prior to Angelini Ventures, he worked for Lundbeck A/S as Director of Corporate Business Development and Strategy. Further positions prior to this include Global Business Development at UCB as well as Life Science Ventures at Sunstone Capital. Thomas Thestrup received his Ph.D. from the Max Planck Institute of Neurobiology in Munich. 

For more information about Fresenius Ventures, please see: fresenius-ventures.com 

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

 

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

 

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Dr. Michael Moser, Dr. Christian Pawlu

Chairman of the Supervisory Board: Wolfgang Kirsch

Meet AskFRE!

AskFRE is the AI powered Investor Relations assistant from Fresenius, designed to make capital markets information easier and faster to access.

Integrated directly into each Investor Relations subpage, AskFRE allows you to ask questions in natural language and receive direct answers on financial results, company updates and other Investor Relations topics – available 24/7.

All responses are based exclusively on publicly available Fresenius disclosures.

By providing a faster and more intuitive way to navigate financial information, AskFRE supports transparent, timely and user focused communication – and enhances the overall digital Investor Relations experience at Fresenius.

You can access AskFRE on each Investors subpage by clicking the chatbot icon in the lower right corner of your screen.
 

What you need to know

  • Languages: Available in English and German (use the standard language switch in the top right corner of the website)
  • Coverage: Information from the last five years up to today
  • Sources: Each answer includes the exact source reference (e.g. document and page number)
  • Data basis: Only publicly available content from the Fresenius Investor Relations website (HTML pages and PDF documents)
  • Data protection: Please access all information here. 

Important notice: AI generated responses may be incomplete or contain inaccuracies. For more information, please refer to the Terms of Use.

Feedback: Suggestions for improvement, missing content or functional issues – please contact us at ir-fre@fresenius.com.

 

How to use AskFRE

To get the most accurate results, we recommend:

  • Ask precise questions, including a specific topic and, if relevant, a time frame
  • Use the source links provided to directly access the underlying documents (e.g. Annual Reports or presentations)
  • Refine your question if the answer is too broad or not specific enough 

 

Try some of these example questions to interact with AskFRE:

  • What is #FutureFresenius about?
  • What are the main business updates from the Fresenius Q1 2026 results?
  • How many hospitals does Fresenius Helios operate in Germany?

 

Contact

Nick Stone Head of Investor Relations Fresenius SE
Nick Stone

Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com

International financial analysts cover Fresenius SE & Co. KGaA and publish reports and updates on the development of its business and its shares. Once a quarter, VARA Research creates an up-to-date consensus from these various forecasts. An interactive and downloadable set of the consensus data for Fresenius SE & Co. KGaA can be found on Vara Research.       

Event

November 04, 2026 | Bad Homburg, Germany

Fresenius Conference Call Event
Conference Call Q3 2026

The webcast with senior management will take place at 1:30 p.m. CET.

Webcast Q3/26 Aide Memoire Presentation Investor News Q3/26 Key Figures Q3/26 Transcript Import (ICS)
Michael Sen - CEO of Fresenius SE & Co. KGaA

Fresenius delivered another excellent quarter, underscoring the strength and consistency of our execution. […] This performance enables us to improve our Core EPS outlook and raise our Group EBIT margin indication. Our strategy is translating into measurable results. Kabi’s Growth Vectors delivered 9% organic growth, led by Biopharma at 29%, while Helios achieved strong growth and margin expansion. We are progressing #FutureFresenius with disciplined investments, including the acquisition of the remaining 45% of mAbxience and our strategic agreement with WuXi Biologics, which will significantly expand and accelerate our biosimilars pipeline. […]”

 

Michael Sen, CEO Fresenius

Financial Highlights Q3/2026

Group Revenue 1

€ 5803 m

+5% 1, 2

Q3/25: €5,477 m

Group EBIT 1

€ 638 m

+10% 4

Q3/25: €574 m

Core Net income 1, 3

€ 403 m

+14% 4

Q3/25: €351 m

Core EPS 1, 3

€ 0.72

+14% 4

Q3/25: €0.62

KABI Revenue 1

€ 2304 m

+6% 2

Q3/25: €2,141 m

HELIOS Revenue 1

€ 3405 m

+5% 2

Q3/25: €3,240 m

1 Before special items

2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

3 Excluding Fresenius Medical Care and Vitrea

4 Constant currency growth

Visitors to an investor conference stand together at bar tables in the reception hall and chat with each other (photo).

Investor Feedback

Open dialogue is valuable for us. 

You can submit your feedback quickly and easily using the link below (anonymously if you prefer). 

You will be redirected to QuantiFire which conducts this survey in own controllership. 
 

News

Stay Connected with Fresenius Investor Relations on LinkedIn

Follow Fresenius Investor Relations for expert insights and latest news that contribute to the Fresenius equity story, and exclusive content from our team. Join our growing community and be part of the conversation!

 

Fresenius Investor Relations LinkedIn Posts

Fresenius announced today that the Company's Q2 2026 Aide Memoire is now available on the Company's financial results section.

As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.

The German Bundestag and Bundesrat approved the Act to Stabilize Contributions Rates in the Statutory Health Insurance System (GKV-Beitragssatzstabilisierungsgesetz) on July 10, 2026. This completes the parliamentary process.

Fresenius’ perspective in brief: 

  • Fresenius’ Full Year 2026 guidance is unchanged.
  • The approved Act preserves annual hospital reimbursement growth, and on balance, is more favourable than the Cabinet Draft, confirming the direction the Company flagged in April 2026.
  • Fresenius Helios’ revenue growth and 10-12% EBIT margin ambition as part of the Fresenius Financial Framework remains unchanged.


Please find the full Market Briefing here: Analyst & Consensus.
 

Bonds 2026 – 2034

Issuer

Fresenius SE & Co. KGaA

Currency

€

Issue amount

500,000,000

Value date

July 08, 2026

Maturity

July 08, 2034

Coupon

3.750%

Coupon payment

July 08

Rating

BBB / Baa3 / BBB-

Stock exchange

Luxembourg / Regulated Market

Denomination

1,000

Clearing agency

Clearstream Luxembourg / Euroclear

ISIN Code

XS3435670222

Subscribe to